Ipatasertib-paclitaxel displays potential as first-line treatment for inoperable advanced TNBC
10 Jul 2020
byRoshini Claire Anthony
Treatment with ipatasertib plus paclitaxel in the first-line setting demonstrated a trend toward improved overall survival (OS) compared with paclitaxel alone in women with inoperable locally advanced/metastatic triple-negative breast cancer (TNBC), according to final results of the phase II LOTUS trial.
Ipatasertib-paclitaxel displays potential as first-line treatment for inoperable advanced TNBC
10 Jul 2020
